BioCentury
ARTICLE | Company News

Zymeworks, GlaxoSmithKline deal

May 2, 2016 7:00 AM UTC

Zymeworks granted GlaxoSmithKline an option to license molecules developed using the biotech’s Azymetric bispecific antibody discovery platform. Zymeworks will receive up to $36 million in upfront and...